HDAC1,2 inhibition impairs EZH2- and BBAP- mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma

Oncotarget

Volumn 6, Issue 7, 2015, Pages 4863-4887

  Johnson, Danielle P ^a   Spitz, Gabriella S ^a   Tharkar, Shweta ^a   Quayle, Steven N ^b   Shearstone, Jeffrey R ^b   Jones, Simon ^b   McDowell, Maria E ^a   Wellman, Hannah ^a   Tyler, Jessica K ^c   Cairns, Bradley R ^a   Chandrasekharan, Mahesh B ^a   Bhaskara, Srividya ^a  

^a UNIVERSITY OF UTAH   (United States)

^b Acetylon Pharmaceuticals Inc   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chromatin; DNA repair; Epigenetics; EZH2; HDAC1,2

Indexed keywords

3 DEAZANEPLANOCIN A; ACY 956; ACY 957; B LYMPHOMA AND BAL ASSOCIATED PROTEIN; DOXORUBICIN; GSK 126; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; HISTONE H3K27; HISTONE H4; HISTONE H4K91; METHYLTRANSFERASE INHIBITOR; TRANSCRIPTION FACTOR EZH2; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; DTX3L PROTEIN, HUMAN; EZH2 PROTEIN, HUMAN; HDAC1 PROTEIN, HUMAN; HDAC2 PROTEIN, HUMAN; POLYCOMB REPRESSIVE COMPLEX 2; UBIQUITIN PROTEIN LIGASE;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; CYTOSTASIS; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG SENSITIVITY; G1 PHASE CELL CYCLE CHECKPOINT; GAIN OF FUNCTION MUTATION; GENE EXPRESSION; HISTONE ACETYLATION; HISTONE METHYLATION; HISTONE UBIQUITINATION; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; LYMPHOMA CELL; ADULT; ANTAGONISTS AND INHIBITORS; GENETIC TRANSFECTION; GENETICS; HELA CELL LINE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; METABOLISM; TUMOR CELL LINE;

ADULT; CELL LINE, TUMOR; DNA REPAIR; ENHANCER OF ZESTE HOMOLOG 2 PROTEIN; HELA CELLS; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITORS; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; POLYCOMB REPRESSIVE COMPLEX 2; TRANSFECTION; UBIQUITIN-PROTEIN LIGASES;

EID: 84925013762     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3120     Document Type: Article

References (61)

1. Sabattini E, Bacci F, Sagramoso C and Pileri SA. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica. 2010; 102(3):83-87.
2. Foon KA, Takeshita K and Zinzani PL. Novel therapies for aggressive B-cell lymphoma. Advances in hematology. 2012; 2012:302570.
3. Ci W, Polo JM and Melnick A. B-cell lymphoma 6 and the molecular pathogenesis of diffuse large B-cell lymphoma. Current opinion in hematology. 2008; 15(4):381-390.
4. Thieblemont C and Briere J. MYC, BCL2, BCL6 in DLBCL: impact for clinics in the future? Blood. 2013; 121(12):2165-2166.
5. Caganova M, Carrisi C, Varano G, Mainoldi F, Zanardi F, Germain PL, George L, Alberghini F, Ferrarini L, Talukder AK, Ponzoni M, Testa G, Nojima T, Doglioni C, Kitamura D, Toellner KM, et al. Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis. The Journal of clinical investigation. 2013; 123(12):5009-5022.
6. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, Paul JE, Boyle M, Woolcock BW, Kuchenbauer F, Yap D, Humphries RK, Griffith OL, Shah S, Zhu H, Kimbara M, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet. 2010; 42(2):181-185.
7. Lund K, Adams PD and Copland M. EZH2 in normal and malignant hematopoiesis. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK. 2014; 28(1):44-49.
8. McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, Liu Y, Graves AP, Della Pietra A, 3rd, Diaz E, LaFrance LV, Mellinger M, Duquenne C, Tian X, Kruger RG, McHugh CF, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 2012; 492(7427):108-112.
9. Chapman-Rothe N, Curry E, Zeller C, Liber D, Stronach E, Gabra H, Ghaem-Maghami S and Brown R. Chromatin H3K27me3/H3K4me3 histone marks define gene sets in high-grade serous ovarian cancer that distinguish malignant, tumour-sustaining and chemo-resistant ovarian tumour cells. Oncogene. 2013; 32(38):4586-4592.
10. Pan LN, Lu J and Huang B. HDAC inhibitors: a potential new category of anti-tumor agents. Cell Mol Immunol. 2007; 4(5):337-343.
11. Petrella A, Fontanella B, Carratu A, Bizzarro V, Rodriquez M and Parente L. Histone deacetylase inhibitors in the treatment of hematological malignancies. Mini reviews in medicinal chemistry. 2011; 11(6):519-527.
12. Zain J and O'Connor OA. Targeting histone deacetyalses in the treatment of B- and T-cell malignancies. Investigational new drugs. 2010; 28 Suppl 1:S58-78.
13. Haberland M, Montgomery RL and Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nature reviews Genetics. 2009; 10(1):32-42.
14. van der Vlag J and Otte AP. Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation. Nat Genet. 1999; 23(4):474-478.
15. Takeyama K, Aguiar RC, Gu L, He C, Freeman GJ, Kutok JL, Aster JC and Shipp MA. The BAL-binding protein BBAP and related Deltex family members exhibit ubiquitin-protein isopeptide ligase activity. The Journal of biological chemistry. 2003; 278(24):21930-21937.
16. Juszczynski P, Kutok JL, Li C, Mitra J, Aguiar RC and Shipp MA. BAL1 and BBAP are regulated by a gamma interferon-responsive bidirectional promoter and are overexpressed in diffuse large B-cell lymphomas with a prominent inflammatory infiltrate. Molecular and cellular biology. 2006; 26(14):5348-5359.
17. Yan Q, Dutt S, Xu R, Graves K, Juszczynski P, Manis JP and Shipp MA. BBAP monoubiquitylates histone H4 at lysine 91 and selectively modulates the DNA damage response. Molecular cell. 2009; 36(1):110-120.
18. Yan Q, Xu R, Zhu L, Cheng X, Wang Z, Manis J and Shipp MA. BAL1 and its partner E3 ligase, BBAP, link Poly(ADP-ribose) activation, ubiquitylation, and double-strand DNA repair independent of ATM, MDC1, and RNF8. Molecular and cellular biology. 2013; 33(4):845-857.
19. Dyer MJ, Fischer P, Nacheva E, Labastide W and Karpas A. A new human B-cell non-Hodgkin's lymphoma cell line (Karpas 422) exhibiting both t (14;18) and t(4;11) chromosomal translocations. Blood. 1990; 75(3):709-714.
20. Epstein AL, Levy R, Kim H, Henle W, Henle G and Kaplan HS. Biology of the human malignant lymphomas. IV. Functional characterization of ten diffuse histiocytic lymphoma cell lines. Cancer. 1978; 42(5):2379-2391.
21. Bodor C, O'Riain C, Wrench D, Matthews J, Iyengar S, Tayyib H, Calaminici M, Clear A, Iqbal S, Quentmeier H, Drexler HG, Montoto S, Lister AT, Gribben JG, Matolcsy A and Fitzgibbon J. EZH2 Y641 mutations in follicular lymphoma. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK. 2011; 25(4):726-729.
22. Wlodarska I, Aventin A, Ingles-Esteve J, Falzetti D, Criel A, Cassiman JJ, Mecucci C, Van den Berghe H and Marynen P. A new subtype of pre-B acute lymphoblastic leukemia with t(5;12)(q31q33;p12), molecularly and cytogenetically distinct from t(5;12) in chronic myelomonocytic leukemia. Blood. 1997; 89(5):1716-1722.
23. Young MD, Willson TA, Wakefield MJ, Trounson E, Hilton DJ, Blewitt ME, Oshlack A and Majewski IJ. ChIP-seq analysis reveals distinct H3K27me3 profiles that correlate with transcriptional activity. Nucleic acids research. 2011; 39(17):7415-7427.
24. Beguelin W, Popovic R, Teater M, Jiang Y, Bunting KL, Rosen M, Shen H, Yang SN, Wang L, Ezponda T, Martinez-Garcia E, Zhang H, Zheng Y, Verma SK, McCabe MT, Ott HM, et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer cell. 2013; 23(5):677-692.
25. Yang WM, Tsai SC, Wen YD, Fejer G and Seto E. Functional domains of histone deacetylase-3. The Journal of biological chemistry. 2002; 277(11):9447-9454.
26. Wilting RH, Yanover E, Heideman MR, Jacobs H, Horner J, van der Torre J, DePinho RA and Dannenberg JH. Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis. The EMBO journal. 2010; 29(15):2586-2597.
27. Yamaguchi T, Cubizolles F, Zhang Y, Reichert N, Kohler H, Seiser C and Matthias P. Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progression. Genes & development. 2010; 24(5):455-469.
28. Bhaskara S, Jacques V, Rusche JR, Olson EN, Cairns BR and Chandrasekharan MB. Histone deacetylases 1 and 2 maintain S-phase chromatin and DNA replication fork progression. Epigenetics & chromatin. 2013; 6(1):27.
29. Bhaskara S, Chyla BJ, Amann JM, Knutson SK, Cortez D, Sun ZW and Hiebert SW. Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control. Molecular cell. 2008; 30(1):61-72.
30. Bhaskara S and Hiebert SW. Role for histone deacetylase 3 in maintenance of genome stability. Cell Cycle. 2011; 10(5):727-728.
31. Knutson SK, Chyla BJ, Amann JM, Bhaskara S, Huppert SS and Hiebert SW. Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks. The EMBO journal. 2008; 27(7):1017-1028.
32. Bhaskara S, Knutson SK, Jiang G, Chandrasekharan MB, Wilson AJ, Zheng S, Yenamandra A, Locke K, Yuan JL, Bonine-Summers AR, Wells CE, Kaiser JF, Washington MK, Zhao Z, Wagner FF, Sun ZW, et al. Hdac3 is essential for the maintenance of chromatin structure and genome stability. Cancer cell. 2010; 18(5):436-447.
33. Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, Karuturi RK, Tan PB, Liu ET and Yu Q. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes & development. 2007; 21(9):1050-1063.
34. Kikuchi J, Takashina T, Kinoshita I, Kikuchi E, Shimizu Y, Sakakibara-Konishi J, Oizumi S, Marquez VE, Nishimura M and Dosaka-Akita H. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells. Lung cancer. 2012; 78(2):138-143.
35. Xie Z, Bi C, Cheong LL, Liu SC, Huang G, Zhou J, Yu Q, Chen CS and Chng WJ. Determinants of sensitivity to DZNep induced apoptosis in multiple myeloma cells. PloS one. 2011; 6(6):e21583.
36. Fujiwara T, Saitoh H, Inoue A, Kobayashi M, Okitsu Y, Katsuoka Y, Fukuhara N, Onishi Y, Ishizawa K, Ichinohasama R and Harigae H. 3-Deazaneplanocin A (DZNep), an inhibitor of S-adenosylmethionine-dependent methyltransferase, promotes erythroid differentiation. The Journal of biological chemistry. 2014; 289(12):8121-8134.
37. Fiskus W, Wang Y, Sreekumar A, Buckley KM, Shi H, Jillella A, Ustun C, Rao R, Fernandez P, Chen J, Balusu R, Koul S, Atadja P, Marquez VE and Bhalla KN. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood. 2009; 114(13):2733-2743.
38. Bradley WD, Arora S, Busby J, Balasubramanian S, Gehling VS, Nasveschuk CG, Vaswani RG, Yuan CC, Hatton C, Zhao F, Williamson KE, Iyer P, Mendez J, Campbell R, Cantone N, Garapaty-Rao S, et al. EZH2 Inhibitor Efficacy in Non-Hodgkin's Lymphoma Does Not Require Suppression of H3K27 Monomethylation. Chemistry & biology. 2014; 21(11):1463-1475.
39. Elkholi R, Floros KV and Chipuk JE. The Role of BH3-Only Proteins in Tumor Cell Development, Signaling, and Treatment. Genes & cancer. 2011; 2(5):523-537.
40. Bolden JE, Shi W, Jankowski K, Kan CY, Cluse L, Martin BP, MacKenzie KL, Smyth GK and Johnstone RW. HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses. Cell death & disease. 2013; 4:e519.
41. Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, McKeon F and Jacks T. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature. 2002; 416(6880):560-564.
42. Kinner A, Wu W, Staudt C and Iliakis G. Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic acids research. 2008; 36(17):5678-5694.
43. Chou DM, Adamson B, Dephoure NE, Tan X, Nottke AC, Hurov KE, Gygi SP, Colaiacovo MP and Elledge SJ. A chromatin localization screen reveals poly (ADP ribose)-regulated recruitment of the repressive polycomb and NuRD complexes to sites of DNA damage. Proc Natl Acad Sci U S A. 2010; 107(43):18475-18480.
44. Miller KM, Tjeertes JV, Coates J, Legube G, Polo SE, Britton S and Jackson SP. Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining. Nat Struct Mol Biol. 2010; 17(9):1144-1151.
45. Campbell S, Ismail IH, Young LC, Poirier GG and Hendzel MJ. Polycomb repressive complex 2 contributes to DNA double-strand break repair. Cell Cycle. 2013; 12(16):2675-2683.
46. Qi W, Chan H, Teng L, Li L, Chuai S, Zhang R, Zeng J, Li M, Fan H, Lin Y, Gu J, Ardayfio O, Zhang JH, Yan X, Fang J, Mi Y, et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci U S A. 2012; 109(52):21360-21365.
47. Clozel T, Yang S, Elstrom RL, Tam W, Martin P, Kormaksson M, Banerjee S, Vasanthakumar A, Culjkovic B, Scott DW, Wyman S, Leser M, Shaknovich R, Chadburn A, Tabbo F, Godley LA, et al. Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer discovery. 2013; 3(9):1002-1019.
48. Shogren-Knaak M, Ishii H, Sun JM, Pazin MJ, Davie JR and Peterson CL. Histone H4-K16 acetylation controls chromatin structure and protein interactions. Science. 2006; 311(5762):844-847.
49. Burgess RJ and Zhang Z. Histone chaperones in nucleosome assembly and human disease. Nat Struct Mol Biol. 2013; 20(1):14-22.
50. Ye J, Ai X, Eugeni EE, Zhang L, Carpenter LR, Jelinek MA, Freitas MA and Parthun MR. Histone H4 lysine 91 acetylation a core domain modification associated with chromatin assembly. Molecular cell. 2005; 18(1):123-130.
51. Hyland EM, Cosgrove MS, Molina H, Wang D, Pandey A, Cottee RJ and Boeke JD. Insights into the role of histone H3 and histone H4 core modifiable residues in Saccharomyces cerevisiae. Molecular and cellular biology. 2005; 25(22):10060-10070.
52. Moser MA, Hagelkruys A and Seiser C. Transcription and beyond: the role of mammalian class I lysine deacetylases. Chromosoma. 2014; 123(1-2):67-78.
53. Huen MS and Chen J. ATM Creates a veil of transcriptional silence. Cell. 2010; 141(6):924-926.
54. Vissers JH, van Lohuizen M and Citterio E. The emerging role of Polycomb repressors in the response to DNA damage. Journal of cell science. 2012; 125(Pt 17):3939-3948.
55. Shanbhag NM, Rafalska-Metcalf IU, Balane-Bolivar C, Janicki SM and Greenberg RA. ATM-dependent chromatin changes silence transcription in cis to DNA double-strand breaks. Cell. 2010; 141(6):970-981.
56. Gieni RS, Ismail IH, Campbell S and Hendzel MJ. Polycomb group proteins in the DNA damage response: a link between radiation resistance and "stemness". Cell Cycle. 2011; 10(6):883-894.
57. Chapman JR, Taylor MR and Boulton SJ. Playing the end game: DNA double-strand break repair pathway choice. Molecular cell. 2012; 47(4):497-510.
58. Aguiar RC, Yakushijin Y, Kharbanda S, Salgia R, Fletcher JA and Shipp MA. BAL is a novel risk-related gene in diffuse large B-cell lymphomas that enhances cellular migration. Blood. 2000; 96(13):4328-4334.
59. Tang J, Cho NW, Cui G, Manion EM, Shanbhag NM, Botuyan MV, Mer G and Greenberg RA. Acetylation limits 53BP1 association with damaged chromatin to promote homologous recombination. Nat Struct Mol Biol. 2013; 20(3):317-325.
60. Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematology / the Education Program of the American Society of Hematology American Society of Hematology Education Program. 2011; 2011:498-505.
61. Zhang Y, Adachi M, Kawamura R and Imai K. Bmf is a possible mediator in histone deacetylase inhibitors FK228 and CBHA-induced apoptosis. Cell death and differentiation. 2006; 13(1):129-140.